kneat.com (TSE:KSI) Stock Rating Upgraded by Cibc World Mkts

kneat.com (TSE:KSI) was upgraded by stock analysts at Cibc World Mkts to a “strong-buy” rating in a research note issued on Tuesday, Zacks.com reports.

Other analysts have also recently issued reports about the stock. Ventum Cap Mkts upgraded shares of kneat.com to a “strong-buy” rating in a report on Wednesday, August 7th. CIBC set a C$6.00 target price on shares of kneat.com and gave the company an “outperform” rating in a research note on Tuesday.

kneat.com Trading Up 0.6 %

kneat.com stock opened at C$4.80 on Tuesday. kneat.com has a 52 week low of C$2.68 and a 52 week high of C$5.17. The company has a debt-to-equity ratio of 95.14, a quick ratio of 1.50 and a current ratio of 1.47. The firm has a market capitalization of C$412.80 million, a price-to-earnings ratio of -30.00, a P/E/G ratio of 597.67 and a beta of 1.08. The company has a 50 day moving average price of C$4.76 and a 200 day moving average price of C$4.44.

kneat.com (TSE:KSI) last issued its earnings results on Tuesday, August 6th. The company reported C($0.04) EPS for the quarter, hitting the consensus estimate of C($0.04). kneat.com had a negative return on equity of 51.13% and a negative net margin of 31.19%. The business had revenue of C$11.68 million during the quarter, compared to analysts’ expectations of C$11.45 million. Research analysts forecast that kneat.com will post -0.12 EPS for the current year.

About kneat.com

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.